Patent · US Active

Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects

US12129299B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignees

OncoC4, Inc. · US
UNIVERSITY OF MARYLAND, BALTIMORE · US

Inventors

Yang Liu · Columbus, US
Pan Zheng · Ann Arbor, US
Fei Tang · Washington, US
Mingyue Liu · Shanghai, CN
Martin Devenport · Gaithersburg, US
Xuexiang Du · Baltimore, US
Yan Zhang · New Albany, US

Key dates

Filing date	Jan 29, 2019
Grant date	Oct 29, 2024
Priority date	—
Expiry date	Nov 12, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.